Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McMaster University

$27,000.00

Determination of cell responses to different components of BoHV-1

FY 2025-26

Summary
Oncolytic viruses (OVs) are a promising cancer therapy that takes advantage of cancer cells' increased susceptibility to viral attack due to disrupted metabolic pathways and reduced antiviral responses. Although OV activity was one attributed to direct oncolysis, recent evidence shows that immune system activation causing immunogenic cell death (ICD) plays a significant role. In particular, bovine herpesvirus type-1 (BoHV-1) has been shown to extend the life of tumor-bearing mice regardless of viral replication. This suggests that BoHV-1 anti-cancer activity is due to ICD rather than cancer cell lysis. However, the exact mechanisms of ICD triggered by BoHV-1 remain unclear. The goal of the proposed research is to determine the mechanisms of ICD by comparing the effect of BoHV-1 components on cell responses. Through this work, I will test the hypothesis that viral replication of BoHV-1 is not necessary for triggering ICD and identify the characteristics of BoHV-1 that drive therapeutic outcomes across cancer types. This will be done by assessing the transcriptional responses of 6 cancer cell lines to live, UV-inactivated, and L-particle BoHV-1. Live virus evaluates responses to replication, UV- treated virus evaluates responses to viral genomes without replication and L-particles (viral particles lacking genome-containing capsids) evaluates responses to membrane perturbation/entry. Results of this research will guide oncolytic virotherapy design and support the development of more effective cancer treatments. Understanding how BoHV-1 components modulate tumor immunity could also identify response biomarkers, improving patient selection for oncolytic virotherapy.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
577042
Name
Brunsting Kara L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Determination of cell responses to different components of BoHV-1
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cancer Immunology; Herpes Simplex Virus; In Vitro Cancer Models; Oncolytic Virotherapy; Transcriptomics
Abstract
Oncolytic viruses (OVs) are a promising cancer therapy that takes advantage of cancer cells' increased susceptibility to viral attack due to disrupted metabolic pathways and reduced antiviral responses. Although OV activity was one attributed to direct oncolysis, recent evidence shows that immune system activation causing immunogenic cell death (ICD) plays a significant role. In particular, bovine herpesvirus type-1 (BoHV-1) has been shown to extend the life of tumor-bearing mice regardless of viral replication. This suggests that BoHV-1 anti-cancer activity is due to ICD rather than cancer cell lysis. However, the exact mechanisms of ICD triggered by BoHV-1 remain unclear. The goal of the proposed research is to determine the mechanisms of ICD by comparing the effect of BoHV-1 components on cell responses. Through this work, I will test the hypothesis that viral replication of BoHV-1 is not necessary for triggering ICD and identify the characteristics of BoHV-1 that drive therapeutic outcomes across cancer types. This will be done by assessing the transcriptional responses of 6 cancer cell lines to live, UV-inactivated, and L-particle BoHV-1. Live virus evaluates responses to replication, UV- treated virus evaluates responses to viral genomes without replication and L-particles (viral particles lacking genome-containing capsids) evaluates responses to membrane perturbation/entry. Results of this research will guide oncolytic virotherapy design and support the development of more effective cancer treatments. Understanding how BoHV-1 components modulate tumor immunity could also identify response biomarkers, improving patient selection for oncolytic virotherapy.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brunsting, Kara L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~